A Phase 1/2, First-in-Human, Open-label, Assessor-Masked, Randomized, Controlled, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects with Stargardt Disease (ST
Clinical Trial Grant
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
SpliceBio, SL
Start Date
February 21, 2025
End Date
February 28, 2030
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
SpliceBio, SL
Start Date
February 21, 2025
End Date
February 28, 2030